mammaprint dna microarray-based test for prognosis of her2þ early breast cancers (Agendia BV)
90
Structured Review
Agendia BV
mammaprint dna microarray-based test for prognosis of her2þ early breast cancers
Mammaprint Dna Microarray Based Test For Prognosis Of Her2þ Early Breast Cancers, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+breast+cancer+test/mammaprint+dna+microarray+based+test+for+prognosis+of+her2%C3%BE+early+breast+cancers/pm20346697-199-14-13
Average 90 stars, based on 1 article reviews
Mammaprint Dna Microarray Based Test For Prognosis Of Her2þ Early Breast Cancers, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+breast+cancer+test/mammaprint+dna+microarray+based+test+for+prognosis+of+her2%C3%BE+early+breast+cancers/pm20346697-199-14-13
Average 90 stars, based on 1 article reviews
mammaprint dna microarray-based test for prognosis of her2þ early breast cancers - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Microarray:Article Title: Identification of a gene expression profile that differentiates ischemic and nonischemic cardiomyopathy Article Snippet: Gene Expression:Article Title: Identification of a gene expression profile that differentiates ischemic and nonischemic cardiomyopathy Article Snippet: |